Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis's diabetes pill Eucreas has received approval from the EU, following approval of galvus, one of the drug's ingredients, according to Reuters.
Subscribe to our email newsletter
Eucreas is a combination of metformin, which decreases the production of sugar by the liver and increases insulin sensitivity, and galvus, a member of DPP-4 inhibitors associated with liver problems.
Novartis said: “The approval comes after the company proposed changes to the EU label recommending that liver monitoring should be conducted.”